GlaxoSmithKline (GSK) has released an update.
GlaxoSmithKline (GSK) has issued a correction to a previous announcement regarding the shareholding of David Redfern, the company’s Chief Strategy Officer. The amendment pertains to the share price in a recent transaction where Redfern acquired shares following dividend reinvestment. The transaction occurred on the London Stock Exchange, with further details unchanged from the original report.
For further insights into GSK stock, check out TipRanks’ Stock Analysis page.
